Chiasma Inc. (NASDAQ:CHMA)’s share price shot up 2.5% during mid-day trading on Thursday . The stock traded as high as $2.87 and last traded at $2.82, with a volume of 78,734 shares trading hands. The stock had previously closed at $2.75.

Several research firms have recently issued reports on CHMA. Zacks Investment Research raised shares of Chiasma from a “sell” rating to a “hold” rating in a research note on Tuesday, April 19th. William Blair downgraded shares of Chiasma from an “outperform” rating to a “market perform” rating in a research note on Monday, April 18th. Barclays PLC downgraded shares of Chiasma from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $40.00 to $5.50 in a research note on Monday, April 25th. Cowen and Company downgraded shares of Chiasma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 19th. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $9.00 price target (down previously from $43.00) on shares of Chiasma in a research note on Monday, April 18th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. Chiasma has a consensus rating of “Hold” and an average price target of $19.70.

The firm has a 50 day moving average of $2.91 and a 200-day moving average of $7.59. The stock’s market capitalization is $67.80 million.

Chiasma (NASDAQ:CHMA) last released its earnings results on Wednesday, May 11th. The company reported ($0.71) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.08. On average, equities analysts anticipate that Chiasma Inc. will post ($2.66) EPS for the current year.

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.